ECC: PICASSO 3 Trial for Metastatic Soft-Tissue Sarcoma Yields Disappointing Results

Article

The combination of palifosfamide and doxorubicin was no better than doxorubicin and placebo in the phase III PICASSO 3 trial of patients with metastatic soft-tissue sarcoma.

[[{"type":"media","view_mode":"media_crop","fid":"17912","attributes":{"alt":"","class":"media-image","id":"media_crop_486389433632","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"1159","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":"Soft-tissue sarcoma photographed through an electron microscope.","typeof":"foaf:Image"}}]]The combination of palifosfamide and doxorubicin was no better than doxorubicin and placebo in the phase III PICASSO 3 trial of patients with metastatic soft-tissue sarcoma.

Palifosfamide is a bi-functional DNA alkylating agent with activity against multiple tumor types. It is the active metabolite of ifosfamide, and thus bypasses resistance pathways. The drug showed promising results in a phase II study of the same combination with doxorubicin vs doxorubicin alone; in that trial, the hazard ratio (HR) for death was 0.79 in favor of palifosfamide, and 40% of patients were alive after 2 years compared with 30% in the control group. Results of the new PICASSO 3 study were presented by Christopher Ryan, MD, of the Knight Cancer Institute at the Oregon Health & Science University in Portland, at the European Cancer Congress (ECC) in Amsterdam.

The new study included 447 patients with metastatic soft-tissue sarcoma treated at 113 centers around the world. Patients were randomized to either the study combination of palifosfamide 150 mg/m2 on days 1, 2, and 3 every 21 days for up to 6 cycles and doxorubicin 75 mg/m2 (226 patients) or doxorubicin and placebo (221 patients).

The median progression-free survival was 5.98 months for the study group compared with 5.23 months for the placebo group, for an HR of 0.87 (95% CI, 0.70-1.07; P = 0.18). Overall survival, a secondary endpoint, was also no different between the groups, at 15.91 months for the palifosfamide group and 16.89 months for the placebo patients (HR = 1.05, 95% CI, 0.79-1.39; P = 0.74).

The toxicities were similar across the two groups; 17.8% of patients in the palifosfamide group experienced febrile neutropenia, compared with only 9.8% for placebo patients. Other common adverse events included nausea, constipation, fatigue, and anemia, and grade 3 adverse events included neutropenia, febrile neutropenia, nausea, and several others.

Ziopharm, the company that sponsored the trial, has ceased development of palifosfamide for soft-tissue sarcoma based on these results, but the drug is still being tested for other indications including small-cell lung cancer in combination with carboplatin and etoposide.

Study Details

No crossover between the two study arms was allowed in PICASSO 3. Progression-free survival was evaluated based on RECIST v1.1 criteria by independent and blinded radiographic review. Six percent of patients had synovial disease; 34% had leiomyosarcoma, and the remaining 60% presented with other soft-tissue sarcomas. The patients were also stratified by age, and 26% of the total cohort were aged at least 65 years. Subgroup analyses of progression-free and overall survival are ongoing and were not presented at ECC.

Related Videos
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Related Content